Loading clinical trials...
Loading clinical trials...
Phase II Study of the Histone-deacetylase Inhibitor ITF2357 in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Conditions
Interventions
histone deacetylase inhibitor (ITF2357)
Locations
1
Italy
Istituto Nazionale per lo studio e la cura dei Tumori
Milan, Italy
Start Date
May 1, 2007
Primary Completion Date
March 1, 2009
Completion Date
March 1, 2009
Last Updated
January 27, 2022
NCT06667687
NCT05618925
NCT05623982
NCT03314974
NCT06014073
NCT04586478
Lead Sponsor
Italfarmaco
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions